Abstract
Mitochondrial dysfunction is one of the major pathological changes seen in Alzheimer’s disease (AD). Amyloid beta-peptide (Aβ), a neurotoxic peptide, accumulates in the brain of AD subjects and mediates mitochondrial and neuronal stress. Therefore, protecting mitochondrion from Aβ-induced toxicity holds potential benefits for halting and treating and perhaps preventing AD. Here, we report that administration of ginsenoside Rg1, a known neuroprotective drug, to primary cultured cortical neurons, rescues Aβ-mediated mitochondrial dysfunction as shown by increases in mitochondrial membrane potential, ATP levels, activity of cytochrome c oxidase (a key enzyme associated with mitochondrial respiratory function), and decreases in cytochrome c release. The protective effects of Rg1 on mitochondrial dysfunction correlate to neuronal injury in the presence of Aβ. This finding suggests that ginsenoside Rg1 may attenuate Aβ-induced neuronal death through the suppression of intracellular mitochondrial oxidative stress and may rescue neurons in AD.
Keywords: Alzheimer’s disease, oligomeric beta-amyloid peptide1-42, mitochondria, ginsenoside Rg1
Current Alzheimer Research
Title:Ginsenoside Rg1 Attenuates Oligomeric Aβ1-42-Induced Mitochondrial Dysfunction
Volume: 9 Issue: 3
Author(s): Tianwen Huang, Fang Fang, Limin Chen, Yuangui Zhu, Jing Zhang, Xiaochun Chen and Shirley Shidu Yan
Affiliation:
Keywords: Alzheimer’s disease, oligomeric beta-amyloid peptide1-42, mitochondria, ginsenoside Rg1
Abstract: Mitochondrial dysfunction is one of the major pathological changes seen in Alzheimer’s disease (AD). Amyloid beta-peptide (Aβ), a neurotoxic peptide, accumulates in the brain of AD subjects and mediates mitochondrial and neuronal stress. Therefore, protecting mitochondrion from Aβ-induced toxicity holds potential benefits for halting and treating and perhaps preventing AD. Here, we report that administration of ginsenoside Rg1, a known neuroprotective drug, to primary cultured cortical neurons, rescues Aβ-mediated mitochondrial dysfunction as shown by increases in mitochondrial membrane potential, ATP levels, activity of cytochrome c oxidase (a key enzyme associated with mitochondrial respiratory function), and decreases in cytochrome c release. The protective effects of Rg1 on mitochondrial dysfunction correlate to neuronal injury in the presence of Aβ. This finding suggests that ginsenoside Rg1 may attenuate Aβ-induced neuronal death through the suppression of intracellular mitochondrial oxidative stress and may rescue neurons in AD.
Export Options
About this article
Cite this article as:
Huang Tianwen, Fang Fang, Chen Limin, Zhu Yuangui, Zhang Jing, Chen Xiaochun and Shidu Yan Shirley, Ginsenoside Rg1 Attenuates Oligomeric Aβ1-42-Induced Mitochondrial Dysfunction, Current Alzheimer Research 2012; 9 (3) . https://dx.doi.org/10.2174/156720512800107636
DOI https://dx.doi.org/10.2174/156720512800107636 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Deep Brain Stimulation for Alzheimer’s Disease
Current Alzheimer Research Lithium - Pharmacological and Toxicological Aspects: The Current State of the Art
Current Medicinal Chemistry Subject Index to Volume 1
Current Vascular Pharmacology Beyond Acetylcholinesterase Inhibitors for Treating Alzheimer's Disease: α7-nAChR Agonists in Human Clinical Trials
Current Pharmaceutical Design Enriched Environments for Rodents and their Interaction with Nicotine Administration
Current Drug Abuse Reviews Platelet Turnover in Atherothrombotic Disease
Current Pharmaceutical Design Tau Truncation is a Productive Posttranslational Modification of Neurofibrillary Degeneration in Alzheimer’s Disease
Current Alzheimer Research Chemokines and Brain Functions
Current Drug Targets - Inflammation & Allergy An Overview and Therapeutic Promise of Nutraceuticals Against Sports-Related Brain Injury
Current Molecular Pharmacology Patent Selections
Recent Patents on Drug Delivery & Formulation Indications for Surgery and Operative Techniques in Infective Endocarditis in the Present Day
Infectious Disorders - Drug Targets Prevalence of Comorbid Anxiety Disorders in Schizophrenia Spectrum Disorders: A Literature Review
Current Psychiatry Reviews Targets of Anti-glucocorticoid Therapy for Stress-related Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Therapeutic Potential of Vasoactive Intestinal Peptide and its Receptors in Neurological Disorders
CNS & Neurological Disorders - Drug Targets AβPP-induced UPR Transcriptomic Signature of Glial Cells to Oxidative Stress as an Adaptive Mechanism to Preserve Cell Function and Survival
Current Alzheimer Research The Glutathione System and its Regulation by Neurohormone Melatonin in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry A Clinician’s Guide to Monoamine Oxidase Inhibitors
Current Psychiatry Reviews Oxidative Stress in Traumatic Brain Injury
Current Medicinal Chemistry Sugars that Glow in the Dark: Fluorescent Tagged Glucose Bioprobes and their Facilitation of the Drug Discovery Process
Current Medicinal Chemistry Impact of the Presence of Select Cardiovascular Risk Factors on Cognitive Changes among Dementia Subtypes
Current Alzheimer Research